| 11/07/25 | GSK | 07:00:05 | 11 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 10/07/25 | GSK | 07:00:05 | 10 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 09/07/25 | GSK | 07:00:04 | 9 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 08/07/25 | GSK | 07:00:05 | 8 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 07/07/25 | GSK | 16:00:01 | 7 Jul 2025 | | GSK | GSK completes acquisition of efimosfermin for SLD | GSK PLC | RNS |
| 07/07/25 | GSK | 07:00:07 | 7 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 04/07/25 | GSK | 07:00:04 | 4 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 03/07/25 | GSK | 07:00:08 | 3 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 02/07/25 | GSK | 07:00:04 | 2 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 01/07/25 | GSK | 15:00:01 | 1 Jul 2025 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 01/07/25 | GSK | 07:00:05 | 1 Jul 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 30/06/25 | GSK | 07:00:06 | 30 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 27/06/25 | GSK | 07:00:04 | 27 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 26/06/25 | GSK | 07:00:05 | 26 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 25/06/25 | GSK | 07:00:08 | 25 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 24/06/25 | GSK | 15:30:00 | 24 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 24/06/25 | GSK | 15:00:00 | 24 Jun 2025 | | GSK | Director Declaration | GSK PLC | RNS |
| 24/06/25 | GSK | 07:00:05 | 24 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 23/06/25 | GSK | 17:50:01 | 23 Jun 2025 | | GSK | Replacement - Director/PDMR Shareholding | GSK PLC | RNS |
| 23/06/25 | GSK | 15:30:00 | 23 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 23/06/25 | GSK | 08:30:08 | 23 Jun 2025 | | GSK | Replacement RNS: Linerixibat file accepted by EMA | GSK PLC | RNS |
| 23/06/25 | GSK | 08:18:31 | 23 Jun 2025 | | GSK | GSK Submits Arexvy for adults 18+ with EMA | GSK PLC | RNS |
| 23/06/25 | GSK | 07:00:06 | 23 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 20/06/25 | GSK | 07:00:06 | 20 Jun 2025 | | GSK | Arexvy filed in Japan for 18-49 at increased risk | GSK PLC | RNS |
| 20/06/25 | GSK | 07:00:04 | 20 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 19/06/25 | GSK | 07:00:04 | 19 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 18/06/25 | GSK | 07:00:07 | 18 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 17/06/25 | GSK | 07:00:05 | 17 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 16/06/25 | GSK | 07:00:08 | 16 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 13/06/25 | GSK | 15:30:00 | 13 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 13/06/25 | GSK | 07:00:05 | 13 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 13/06/25 | GSK | 07:00:02 | 13 Jun 2025 | | GSK | GSK submits Arexvy for adults 18+ with EMA | GSK PLC | RNS |
| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 12/06/25 | GSK | 07:00:06 | 12 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 11/06/25 | GSK | 15:30:01 | 11 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 11/06/25 | GSK | 07:00:05 | 11 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 10/06/25 | GSK | 07:00:05 | 10 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 09/06/25 | GSK | 07:00:05 | 9 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 06/06/25 | GSK | 07:00:08 | 6 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 05/06/25 | GSK | 07:00:07 | 5 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 04/06/25 | GSK | 07:00:07 | 4 Jun 2025 | | GSK | GSK - second tranche of share buyback programme | GSK PLC | RNS |
| 04/06/25 | GSK | 07:00:06 | 4 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 03/06/25 | GSK | 07:00:06 | 3 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 02/06/25 | GSK | 15:30:00 | 2 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 02/06/25 | GSK | 15:00:01 | 2 Jun 2025 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 02/06/25 | GSK | 07:00:09 | 2 Jun 2025 | | GSK | Linerixibat file accepted for review by US FDA | GSK PLC | RNS |
| 02/06/25 | GSK | 07:00:07 | 2 Jun 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 30/05/25 | GSK | 07:00:07 | 30 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 29/05/25 | GSK | 07:00:07 | 29 May 2025 | | GSK | Transaction in Own Shares | GSK PLC | RNS |
| 28/05/25 | GSK | 12:00:00 | 28 May 2025 | | GSK | GSK stops Phase 3 trial on cUTIs for efficacy | GSK PLC | RNS |